迪哲医药

688192 SSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

22.6B ($3.3B)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

360.0M

Net Income

-940.0M

Gross Margin

N/A

Op. Margin

-2.6%

Net Margin

-2.6%

ROE

-4.7%

ROA

-54.7%

D/E

7.59

Dividend Yield

N/A

EPS

-2.04

Current Ratio

1.27

Price History

Company Info

Industry	C27医药制造业
Market Segment	STAR Market
Currency	CNY
Fiscal Year	2024

Business Overview

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shanghai, China.

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 迪哲医药

Ticker	688192
Exchange	SSE
Sector	证监会行业分类
Industry	C27医药制造业